ArticlePloS one2016
Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04133519 (The Efficacy and Safety of IBS Digital Behavioral Treatment Study), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy and Safety of IBS Digital Behavioral Treatment Study
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Does Fibre-fix provided to people with irritable bowel syndrome who are consuming a low FODMAP diet improve their gut health, gut microbiome, sleep and mental health? A double-blinded, randomised controlled trial.BMJ open gastroenterology · 2020Trial
- Irritable bowel syndrome and its impact on utilization and outcomes in elective thoracolumbar fusion.Brain & spine · 2026Article
- Diagnostic strategy of irritable bowel syndrome: a low- and middle-income country perspective.Intestinal research · 2024Review
- Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States.Clinical and experimental gastroenterology · 2024Review
- Survey-Based Analysis of the Clinical Treatment Status of Irritable Bowel Syndrome in Korea.Journal of Korean medical science · 2023Article
- Effect of a Daily Collagen Peptide Supplement on Digestive Symptoms in Healthy Women: 2-Phase Mixed Methods Study.JMIR formative research · 2022Article
- Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.Digestive diseases and sciences · 2021Article
- Illness perception and health care use in individuals with irritable bowel syndrome: results from an online survey.BMC family practice · 2021Article
- Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Article
- Healthcare use by 30,000 patients with irritable bowel syndrome (IBS) in France: a 5-year retrospective and one-year prospective national observational study.BMC gastroenterology · 2019Observational
- Colorectal cancer incidence among young adults in England: Trends by anatomical sub-site and deprivation.PloS one · 2019Article
- Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome.Therapeutic advances in gastroenterology · 2019Article
- Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2018Review
- Understanding and Managing IBS and CIC in the Primary Care Setting.Gastroenterology & hepatology · 2018Article
- Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?The American journal of gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIrritable bowel syndrome (IBS) affects nearly one in seven Americans. Significant national variations in care may exist, due to a current lack of standardized diagnosis and treatment algorithms; this can translate into a substantial additional economic burden. The study examines healthcare resource utilization in patients with IBS and in the subset of IBS patients with constipation (IBS-C) and analyzes the variation of IBS care for these patients across the United States (US).
methodsHealthcare resource use (HRU), including gastrointestinal (GI) procedures and tests, all-cause and intestinal-related medical visits, GI specialist visits, and constipation or diarrhea pharmacy prescriptions for IBS patients enrolled in a large US administrative claims database (2001-2012) were analyzed for the 24-month period surrounding first diagnosis. Multivariate regression models, adjusting for age, gender, year of first diagnosis, insurance type, and Charlson comorbidity index, compared HRU across states (each state vs. the average of all other states).
resultsOf 201,322 IBS patients included, 77.2% were female. Mean age was 49.4 years. One in three patients had ≥3 distinct GI medical procedures or diagnostic tests; 50.1% visited a GI specialist. Significant HRU differences were observed in individual states compared to the national average. IBS-C patients had more medical visits, procedures, and pharmacy prescriptions for constipation/diarrhea than IBS patients without constipation.
conclusionsThis study is the first to identify considerable regional variations in IBS healthcare across the US and to note a markedly higher HRU by IBS-C patients than by IBS patients without constipation. Identifying the reasons for these variations may improve quality of care and reduce the economic burden of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.